Press Releases from Antisoma plc (UK) (3 total)
direct/ Antisoma plc (UK) - Antisoma strategy update - joint statement from the …
Future opportunities
Today´s AS1404 licensing deal with Novartis is a great achievement. It is also an important step along the way to making Antisoma a significant and self-sustaining bio-pharmaceutical company. Our recent successes have provided us with an unprecedented opportunity to take our business forward. This will involve further expansion and diversification of our product pipeline. It will also entail a transition towards a business with a substantial role in commercialising…
direct/ Antisoma plc (UK) - Antisoma announces global agreement with Novartis fo …
London, UK: 19 April 2007 - Antisoma plc announced today that it has signed an exclusive global licensing agreement with Novartis for its vascular disrupting agent AS1404 (DMXAA).
Antisoma will receive near-term payments of USD 100 million. USD 75 million will be paid immediately and a further USD 25 million when AS1404 enters a phase III trial in lung cancer.
Antisoma will be eligible for total upfront, development, regulatory and…
direct/ Antisoma to present at Needham & Company Fifth Annual Biotechnology Conf …
13 June 2006, London, UK - Antisoma plc (LSE: ASM; USOTC: ATSMY) today announces that its Chief Executive Officer, Glyn Edwards, will be presenting at the Needham & Company Fifth Annual Biotechnology and Medical Technology Conference in New York, USA.
Mr Edwards´s presentation is scheduled for 13.00 EST on Thursday, June 15, followed by a 30 minute breakout session. A webcast of the presentation will be available to all on…
